Cargando…

Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

BACKGROUND: The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (PILI), delivered via distance video telecon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thurman, Angela John, Potter, Laura A., Kim, Kyoungmi, Tassone, Flora, Banasik, Amy, Potter, Sarah Nelson, Bullard, Lauren, Nguyen, Vivian, McDuffie, Andrea, Hagerman, Randi, Abbeduto, Leonard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175541/ https://www.ncbi.nlm.nih.gov/pubmed/32316911 http://dx.doi.org/10.1186/s11689-020-09315-4

Ejemplares similares

Family and Caregiver Characteristics Contribute to Caregiver Change in Use of Strategies and Growth in Child Spoken Language in a Parent-Implemented Language Intervention in Fragile X Syndrome
por: Potter, Sarah Nelson, et al.
Publicado: (2022)

Distance delivery of a parent-implemented language intervention for young boys with fragile X syndrome
por: Bullard, Lauren, et al.
Publicado: (2017)

The fragile X syndrome–autism comorbidity: what do we really know?
por: Abbeduto, Leonard, et al.
Publicado: (2014)

Narrative language competence in children and adolescents with Down syndrome
por: Channell, Marie Moore, et al.
Publicado: (2015)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome
por: Aishworiya, Ramkumar, et al.
Publicado: (2023)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
por: Abbeduto, Leonard, et al.
Publicado: (2020)

Correction to: Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity
por: Abbeduto, Leonard, et al.
Publicado: (2020)

Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling
por: Thurman, Angela John, et al.
Publicado: (2021)

Specificity: A Phenotypic Comparison of Communication-Relevant Domains Between Youth With Down Syndrome and Fragile X Syndrome
por: del Hoyo Soriano, Laura, et al.
Publicado: (2018)

Fragile X-Associated Neuropsychiatric Disorders (FXAND) in Young Fragile X Premutation Carriers
por: Aishworiya, Ramkumar, et al.
Publicado: (2022)

Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation
por: Wang, Jun Yi, et al.
Publicado: (2022)

Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome
por: Johnson, Devon, et al.
Publicado: (2022)

Maternal Mental Health and Parenting Stress and Their Relationships to Characteristics of the Child With Fragile X Syndrome
por: Bullard, Lauren, et al.
Publicado: (2021)

Mental Health Challenges, Parenting Stress, and Features of the Couple Relationship in Parents of Children With Fragile X Syndrome
por: Potter, Sarah Nelson, et al.
Publicado: (2022)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Concurrent Associations between Expressive Language Ability and Independence in Adolescents and Adults with Fragile X Syndrome
por: Abbeduto, Leonard, et al.
Publicado: (2021)

EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome
por: Proteau-Lemieux, Mélodie, et al.
Publicado: (2021)

Corrigendum: EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome
por: Proteau-Lemieux, Mélodie, et al.
Publicado: (2022)

Genomic studies in fragile X premutation carriers
por: Lozano, Reymundo, et al.
Publicado: (2014)

Expressive language development in adolescents with Down syndrome and fragile X syndrome: change over time and the role of family-related factors
por: del Hoyo Soriano, Laura, et al.
Publicado: (2020)

Neural progenitor cells from an adult patient with fragile X syndrome
por: Schwartz, Philip H, et al.
Publicado: (2005)

The Relationship between Expressive Language Sampling and Clinical Measures in Fragile X Syndrome and Typical Development
por: Shaffer, Rebecca C., et al.
Publicado: (2020)

Metformin treatment in young children with fragile X syndrome
por: Biag, Hazel Maridith B., et al.
Publicado: (2019)

Using Telehealth-Delivered Procedures to Collect a Parent-Implemented Expressive Language Sampling Narrative Task in Monolingual and Bilingual Families With Autism Spectrum Disorder: A Pilot Study
por: del Hoyo Soriano, Laura, et al.
Publicado: (2021)

Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin‐two cases
por: Protic, Dragana, et al.
Publicado: (2019)

Exploring the feasibility of collecting multimodal multiperson assessment data via distance in families affected by fragile X syndrome
por: Bullard, Lauren, et al.
Publicado: (2021)

Prenatal Diagnosis of Fragile X: Can a Full Mutation Allele in the FMR1 Gene Contract to a Normal Size?
por: Manor, Esther, et al.
Publicado: (2017)

Testing the FMR1 Promoter for Mosaicism in DNA Methylation among CpG Sites, Strands, and Cells in FMR1-Expressing Males with Fragile X Syndrome
por: Stöger, Reinhard, et al.
Publicado: (2011)

Intranuclear inclusions in a fragile X mosaic male
por: Pretto, Dalyir I, et al.
Publicado: (2013)

Sequencing the unsequenceable: Expanded CGG-repeat alleles of the fragile X gene
por: Loomis, Erick W., et al.
Publicado: (2013)

New Targeted Treatments for Fragile X Syndrome
por: Protic, Dragana, et al.
Publicado: (2019)

Immune Dysregulation as a Cause of Autoinflammation in Fragile X Premutation Carriers: Link between FMRI CGG Repeat Number and Decreased Cytokine Responses
por: Careaga, Milo, et al.
Publicado: (2014)

Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome
por: Jasoliya, Mittal, et al.
Publicado: (2020)

Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome
por: Famula, Jessica, et al.
Publicado: (2022)

Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome
por: Careaga, Milo, et al.
Publicado: (2014)

Analysis of a Repetitive Language Coding System: Comparisons between Fragile X Syndrome, Autism, and Down Syndrome
por: Hoffmann, Anne, et al.
Publicado: (2022)

Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome
por: Chonchaiya, Weerasak, et al.
Publicado: (2010)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_985ouripuaam2i9ujqsl8364io